None listed
Conditions
Brief summary
It is well established that obesity and elevated blood pressure can lead to impaired vascular function. However, it is less clear how impaired blood vessel function affects cardiovascular and, consequently, blood pressure responses during exercise. Exaggerated blood pressure responses to exercise can be an early risk factor for the development of future hypertension. The aim of this study is to establish a dose/response relationship for the effect of resveratrol on endothelial vasodilator function as measured by flow mediated dilation (FMD) and blood pressure (BP), both at rest and during exercise, in volunteers who are overweight/obese with elevated BP. The results of this study will inform the design of future trials which will explore the effect of combinations of resveratrol and other vasoactive nutrients on cardiovascular and mental health.
Interventions
Volunteers will be required to consume three doses of resveratrol (30, 90 or 270mg on one occasion per dose).
There will be four separate visits (of one hour duration each) to the research centre which will occur with a one week washout between visits. At each visit the participant will consume one dose of resveratrol (or placebo) per visit.
Measurements of endothelial vasodilator function and blood pressure responses to exercise will begin one hour after consumption of each single dose of resv
Volunteers will be required to consume three doses of resveratrol (30, 90 or 270mg on one occasion per dose). There will be four separate visits (of one hour duration each) to the research centre which will occur with a one week washout between visits. At each visit the participant will consume one dose of resveratrol (or placebo) per visit. Measurements of endothelial vasodilator function and blood pressure responses to exercise will begin one hour after consumption of each single dose of resveratrol. These measures will be repeated at each visit. Resveratrol will be administered orally in capsules. Each of the three doses of resveratrol consists of multiple capsules; all capsules that make up a single dose will be consumed at once. Doses will be made up of combinations of 15 and 75 mg resveratrol capsules as follows: 1) 30 mg: 2 capsules of 15 mg + 4 placebo capsules 2) 90 mg: 1 capsule of 75 mg + 1 capsule of 15 mg + 4 placebo 3) 270 mg: 3 capsules of 75 mg + 3 of 15 mg
Sponsors
Professor Peter Howe
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Men or post-menopausal women (self reported cessation of menses for at least 12 months) aged 30 - 70 years. b) Volunteers will be overweight or obese (Body mass index (BMI) ranging from 25kg/m2 to 35kg/m2), and c) have high-normal BP or untreated mild primary hypertension (systolic BP 130-160 mmHg or Diastolic BP 85-100 mmHg) d) but are otherwise healthy. Volunteers will provide a blood sample on the first day of testing to assess blood chemistry, coagulation and hematology outcomes to ensure there are no underlying medical conditions that would influence the study outcomes.
Exclusion criteria
a) have cardiovascular disease, renal disease or diabetes b) take BP lowering medication c) have any other medical condition or treatments (including supplements) which, in the opinion of the investigators, may influence the outcome of the study d) smoke or use nicotine replacement therapy
Outcome results
None listed